Proposed Changes to U.S. Policy on Potential Pandemic Pathogen Oversight and Implementation
Overview
Parasitology
Authors
Affiliations
We propose here changes to the U.S. government policy on potential pandemic pathogen (PPP) oversight and implementation, emphasizing transparency of the review process and the content of the review, publication of the review in advance, responsible publication of enhanced PPP research, high-level signoff on approvals of enhanced PPP experiments, and the need for a significant effort to establish a common international approach to enhanced PPP work. We advocate that the U.S. government recommend, and non-U.S. government funders and journals adopt, a set of best practices that would extend important considerations of biosafety and biosecurity to all work on enhanced potential pandemic pathogens regardless of funding source.
Bridging biosafety and biosecurity gaps: DURC and ePPP policy insights from U.S. institutions.
Gillum D, Tran A, Fletcher J, Vogel K Front Bioeng Biotechnol. 2024; 12():1476527.
PMID: 39398640 PMC: 11467424. DOI: 10.3389/fbioe.2024.1476527.
Beyond Biosecurity by Taxonomic Lists: Lessons, Challenges, and Opportunities.
Millett P, Alexanian T, Brink K, Carter S, Diggans J, Palmer M Health Secur. 2023; 21(6):521-529.
PMID: 37856148 PMC: 10733751. DOI: 10.1089/hs.2022.0109.
The Lancet Commission on lessons for the future from the COVID-19 pandemic.
Sachs J, Abdool Karim S, Aknin L, Allen J, Brosbol K, Colombo F Lancet. 2022; 400(10359):1224-1280.
PMID: 36115368 PMC: 9539542. DOI: 10.1016/S0140-6736(22)01585-9.
Rethinking Gain-of-Function Experiments in the Context of the COVID-19 Pandemic.
Imperiale M, Casadevall A mBio. 2020; 11(4).
PMID: 32769091 PMC: 7419723. DOI: 10.1128/mBio.01868-20.